Post-Polycythemia Vera-Myelofibrosis
Also known as: Post-polycythemia Vera Myelofibrosis(Post-PV MF) / Post polycythaemia vera myelofibrosis / Post-Polycythemia Vera / Post-Polycythaemia Vera / Post-polycythemia Vera (Post-PV) / Post Polycythaemia Myelofibrosis (PPV MF) / Myelofibrosis Due to and Following Polycythemia Vera / Post Polycythemia Myelofibrosis / Post Polycythemia Vera Fibrosis / Post-polycythemia Vera Related Myelofibrosis / Myelofibrosis, Post PV / Post Polycythemia-Vera Myelofibrosis / Post Polycythemia Vera Myelofibrosis / Post Polycythemia Vera-myelofibrosis / Post-Polycythemia Vera Myelofibrosis / Post Polycythemia Myelofibrosis (PPV MF) / Post PV MF / Post-PV MF / Post-polycythemia Vera (Post-PV) Myelofibrosis / Post-polycythemia Vera Myelofibrosis (PPV-MF) / Post-Polycythemia Vera-Myelofibrosis (PPV-MF) / Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) / Post-polycythemia Vera Myelofibrosis (Post-PV MF) / Post-Polycythemia Vera MF (Post-PV-MF) / Post-Polycythemia Vera (PV) MF / Myelofibrosis due to and following polycythemia vera (disorder) / Myelofibrosis / Myelosis non-leukemic / Agnogenic myeloid metaplasia / Myelofibrosis (disorder) / Myelosis-non-leukaemic / Myelosis non-leukaemic
Drug | Drug Name | Drug Description |
---|---|---|
DB08877 | Ruxolitinib | A kinase inhibitor used to treat various types of myelofibrosis, polycythemia vera in patients who have not responded to or cannot tolerate hydroxyurea, and to treat graft-versus-host disease in cases that are refractory to steroid treatment. |